InMode (INMD) Aandelenoverzicht
InMode Ltd. ontwerpt, ontwikkelt, produceert en verkoopt minimaal invasieve esthetische medische producten gebaseerd op haar eigen radiofrequentie ondersteunde lipolyse en diepe subdermale fractionele radiofrequentietechnologieën in de Verenigde Staten, Europa, Azië en internationaal. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 5/6 |
| Toekomstige groei | 0/6 |
| Prestaties in het verleden | 1/6 |
| Financiële gezondheid | 6/6 |
| Dividenden | 0/6 |
Beloningen
Risicoanalyse
INMD Community Fair Values
Create NarrativeSee what 44 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
InMode
31.3% ondergewaardeerd intrinsieke korting
A Clear Case of Mispricing.
View narrativeAN
Published 17 Jun
InMode Ltd. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$14.90 |
| 52 Week Hoogtepunt | US$16.74 |
| 52 Week Laag | US$12.72 |
| Bèta | 1.86 |
| 1 maand verandering | -1.65% |
| 3 maanden verandering | 10.45% |
| 1 Jaar Verandering | 0.27% |
| 3 jaar verandering | -56.06% |
| 5 jaar verandering | -78.90% |
| Verandering sinds IPO | 119.60% |
Recent nieuws en updates
Recent updates
Nieuw narratief • Jun 17
A Clear Case of Mispricing.
A Clear Case of Mispricing – High Cash Cushion and Unjustified Discount Investment Thesis The market is currently treating InMode (NASDAQ: INMD) as a dying aesthetics business, completely ignoring its fortress balance sheet and robust earnings power. From a fundamental "Mispricing" perspective, the current valuation implies that the company’s operating business is worth next to nothing.
Narratiefupdate • May 03
INMD: Buyback Plan And 2026 Guidance Will Support A Measured Outlook
Analysts kept their $15.00 price target for InMode unchanged, noting only minor shifts in inputs such as discount rate, revenue growth, profit margin, and future P/E assumptions as the basis for maintaining their view. What's in the News InMode issued revenue guidance for the first quarter of 2026, with expected revenue in a range of $81.5 million to $81.7 million, and reiterated its full year 2026 revenue outlook of $365 million to $375 million (Corporate Guidance).Narratiefupdate • Apr 19
INMD: Takeover Talks And Buyback Plan Will Shape A Measured Outlook
InMode's updated analyst price target remains at $15.00, with analysts pointing to small shifts in the discount rate, revenue growth assumptions, profit margin, and future P/E as the key drivers behind the reaffirmed valuation view. What's in the News Media report that InMode is in talks to be sold for about US$1.1b to a foreign investment fund, pointing to ongoing interest from financial buyers (Calcalist).Narratiefupdate • Apr 03
INMD: Potential Takeover Talks And Buyback Plan Will Shape A Balanced Outlook
Analysts have maintained their $15.00 price target for InMode, citing small adjustments to assumptions such as the discount rate, revenue growth, profit margin, and future P/E that did not materially affect their overall valuation view. What's in the News Media reports indicate InMode is in talks to be sold for about US$1.1b to a foreign investment fund, highlighting ongoing interest from financial buyers (Calcalist).Narratiefupdate • Mar 20
INMD: Potential Sale Talks And Buyback Plan Will Shape A Measured Outlook
Analysts have kept their $15.00 price target on InMode unchanged, citing only very small tweaks to model inputs around discount rate, revenue growth, profit margin and future P/E assumptions, rather than any major shift in their view of the stock. What's in the News Media report that InMode is in talks to be sold for about US$1.1 billion to a foreign investment fund, according to Calcalist (Calcalist).Narratiefupdate • Mar 05
INMD: Potential Sale And Earnings Guidance Will Shape A Measured Forward View
Analysts have kept their $15.00 price target on InMode unchanged, citing only marginal tweaks to assumptions such as the discount rate, revenue growth, profit margin and future P/E that did not materially alter their overall view of the stock. What's in the News Calcalist reports that InMode is in talks to be sold for about US$1.1b to a foreign investment fund, indicating ongoing interest in potential ownership changes (Calcalist).Narratiefupdate • Feb 19
INMD: Potential Sale Talks And Earnings Guidance Will Shape A Balanced Outlook
Analysts kept their $15.00 price target for InMode steady, citing only slight adjustments in assumptions such as discount rate, revenue growth, profit margin, and future P/E as reasons for maintaining their view rather than making a material change. What's in the News Media report that InMode is in talks to be sold for about US$1.1b to a foreign investment fund, according to Calcalist (Periodical).Seeking Alpha • Feb 18
InMode: Some Green Shoots Appearing, But The Market Hasn't Noticed
Summary InMode Ltd. remains a Strong Buy at current levels, supported by a robust balance sheet, proprietary technology, and international growth. Green shoots include a 2.7% rise in consumables/servicing revenue and 14.5% international sales growth, offsetting possible U.S. market saturation. Management guides for flat 2026 revenue, with new product launches and expanding international footprint positioning INMD for future upside. Despite management frustrations and takeover rumors, INMD's very low valuation and strong cash position offer compelling risk-reward for recovery-focused investors. Read the full article on Seeking AlphaNarratiefupdate • Feb 04
INMD: Potential Sale Talks And Guidance Will Sustain A Cautious Fair Value View
Analysts have kept their price target for InMode steady at US$15.00, with only minor model tweaks to the discount rate, revenue growth, profit margin and assumed future P/E feeding into this unchanged view. What's in the News Media report that InMode is in talks to be sold to a foreign investment fund in a transaction valued at about US$1.1 billion, indicating active interest in the company from financial buyers (Periodical, Calcalist).Narratiefupdate • Jan 21
INMD: Refreshed Guidance And Margin Outlook Will Support A Cautious Fair Value Stance
Analysts now see InMode's fair value holding at $15.00. The refreshed price target framework mainly reflects adjusted assumptions around discount rate, revenue growth, profit margin and future P/E rather than a change in the headline valuation level.Analyse-artikel • Jan 07
InMode (NASDAQ:INMD) Could Be Struggling To Allocate Capital
If you're looking for a multi-bagger, there's a few things to keep an eye out for. In a perfect world, we'd like to see...Narratiefupdate • Jan 06
INMD: Reaffirmed 2025 Revenue Guidance Will Underpin A Cautious Fairly Valued Outlook
Analysts have nudged their price target on InMode slightly higher to US$15.00 from US$15.00. This reflects small tweaks to assumptions on discount rate, revenue growth, profit margin, and future P/E that, in their view, modestly refine rather than overhaul the prior outlook.Narratiefupdate • Dec 13
INMD: Revenue Outlook And Legal Overhang Will Shape A Cautious 2025 Outlook
Analysts have raised their price target on InMode by 1.00 dollar, reflecting improved expectations for a return to modest top line growth and slightly higher long term profitability multiples. What's in the News InMode reaffirmed its full year 2025 revenue outlook, maintaining guidance at $365 million to $375 million.Analyse-artikel • Nov 12
There Might Be More To InMode's (NASDAQ:INMD) Story Than Just Weak Earnings
Shareholders didn't appear too concerned by InMode Ltd.'s ( NASDAQ:INMD ) weak earnings. We did some digging, and we...Analyse-artikel • Jul 31
Should You Think About Buying InMode Ltd. (NASDAQ:INMD) Now?
InMode Ltd. ( NASDAQ:INMD ), might not be a large cap stock, but it saw significant share price movement during recent...Analyse-artikel • Jun 30
An Intrinsic Calculation For InMode Ltd. (NASDAQ:INMD) Suggests It's 36% Undervalued
Key Insights InMode's estimated fair value is US$22.05 based on 2 Stage Free Cash Flow to Equity InMode's US$14.19...Analyse-artikel • May 21
InMode (NASDAQ:INMD) Might Be Having Difficulty Using Its Capital Effectively
What trends should we look for it we want to identify stocks that can multiply in value over the long term? One common...Seeking Alpha • Apr 29
InMode: Equity Value Hinges On Cash, Not Future Prospects (Rating Downgrade)
Summary InMode's Q1 2025 earnings reveal a 3% YoY revenue decline and margin compression, signaling continued macroeconomic pressures and underutilization of installed platforms. Management's revised 2025 guidance lowers profitability expectations, reflecting ongoing challenges in the U.S. market and less profitable international expansion. Despite a strong balance sheet, past strategic missteps and ineffective cash allocation raise concerns about future shareholder value and growth prospects. Given the revenue declines and strategic uncertainties, I downgrade InMode to Hold, recommending caution until significant positive developments occur. Read the full article on Seeking AlphaAnalyse-artikel • Apr 26
Is Now The Time To Look At Buying InMode Ltd. (NASDAQ:INMD)?
While InMode Ltd. ( NASDAQ:INMD ) might not have the largest market cap around , it saw a decent share price growth of...Analyse-artikel • Apr 11
Investors Don't See Light At End Of InMode Ltd.'s (NASDAQ:INMD) Tunnel And Push Stock Down 25%
InMode Ltd. ( NASDAQ:INMD ) shares have had a horrible month, losing 25% after a relatively good period beforehand...Seeking Alpha • Feb 10
InMode: Plastic Surgery Boom, Cash Flow, And Cheap
Summary InMode is significantly undervalued, with strong cash flow, international expansion, and investments in research and marketing driving future revenue and free cash flow growth. The company benefits from the booming non-invasive plastic surgery market, expected to grow at a 14% CAGR from 2023 to 2030. INMD's stock repurchase program and substantial investments in bonds and bank deposits are expected to boost stock price and financial stability. Despite lower 2024 revenue, new product launches and international efforts indicate promising growth potential from 2025 to 2031. Read the full article on Seeking AlphaSeeking Alpha • Jan 28
InMode: A Clear Bargain With Unique Risks
Summary InMode Ltd. boasts superior fundamentals, yet trades at undervalued market multiples due to its unique risk profile. The company is a leader in the global aesthetics market with proprietary RF-based technologies. InMode's robust balance sheet and high profit margins support a substantial margin of safety at current prices, despite risks. Read the full article on Seeking AlphaAnalyse-artikel • Jan 08
An Intrinsic Calculation For InMode Ltd. (NASDAQ:INMD) Suggests It's 50% Undervalued
Key Insights InMode's estimated fair value is US$34.79 based on 2 Stage Free Cash Flow to Equity Current share price of...Seeking Alpha • Dec 12
InMode: Product Origination And Undervaluation Make The Stock A Buy
Summary InMode Ltd. demonstrates impressive net income growth from non-invasive surgical products, with new platforms Define and Envision expected to drive future business growth. The company's innovative technologies in plastic surgery, dermatology, gynecology, and ophthalmology, along with ongoing stock repurchases, make InMode a compelling buy. Strong financials show consistent income growth and significant cash flow, with minimal liabilities, indicating a robust financial position and undervaluation. Expansion into new markets, enhanced sales force, and continuous R&D in new treatment areas promise sustained revenue and free cash flow growth. Read the full article on Seeking AlphaSeeking Alpha • Nov 05
InMode: $25/Share Is Closer Than You Think
Summary Elevated interest rates continue to hurt InMode’s revenue, especially as lease package interest rates haven't fallen yet. Still, future rate cuts could release pent-up demand. InMode continues to buy back shares at a low price, which will boost per-share results. InMode's manufacturing is done in Israel, presenting a risk, but the company has been managing this well despite the war. The stock is undervalued, with only modest FCF/share growth needed to achieve a $25 fair value. And this FCF/share growth can be supported by more buybacks. Organizational shifts don't have me worried at the moment, but they are worth monitoring because they present uncertainty. Read the full article on Seeking AlphaAnalyse-artikel • Nov 01
InMode Ltd. Just Recorded A 17% EPS Beat: Here's What Analysts Are Forecasting Next
InMode Ltd. ( NASDAQ:INMD ) investors will be delighted, with the company turning in some strong numbers with its...Analyse-artikel • Sep 24
InMode (NASDAQ:INMD) Could Be Struggling To Allocate Capital
To find a multi-bagger stock, what are the underlying trends we should look for in a business? One common approach is...
Nieuw narratief • Sep 24
Innovations And Global Expansion Poised To Propel Medical Tech Leader To New Heights
Introduction of IgniteRF and Optimus Max platforms, alongside FDA clearance for Morpheus8, drives revenue growth through market penetration and expanding patient base.Seeking Alpha • Sep 19
InMode Offers High Risk-Reward Opportunity Amid New Products And Rate Cuts (Rating Upgrade)
Summary InMode’s Q2 2024 revenue dropped by 36.5% year-over-year to $86.4 million, underlining macroeconomic challenges. The company revised its full-year 2024 revenue guidance to $430-$440 million due to slower platform rollouts and production delays. Lower interest rates from Federal Reserve cuts could boost demand for InMode's minimally invasive treatments, benefiting from reduced financing costs. New platforms IgniteRF and OptimasMAX are expected to drive future growth, appealing to clinics seeking cost-effective solutions. Despite short-term revenue declines, InMode’s attractive valuation and new growth catalysts position it as a "buy" opportunity. Read the full article on Seeking AlphaSeeking Alpha • Sep 06
InMode Stock: An Inverse Bubble Caused By Short-Term Trouble
Summary InMode stock has significant upside potential due to its low valuation, profitability, share buybacks, and potential benefits from expected interest rate cuts. INMD's business model involves selling high-quality, expensive medical devices for aesthetic procedures, heavily influenced by interest rates due to customer financing. The stock's decline was driven by underutilized buybacks, declining revenue, and high interest rates, but recent buybacks and potential rate cuts offer a brighter outlook. Despite geopolitical risks, InMode's strong cash position, profitability, and the growing aesthetics market make it a long-term investment opportunity. Read the full article on Seeking AlphaSeeking Alpha • Aug 12
InMode: Still Undervalued, But Short-Term Risks Warrant Caution (Rating Downgrade)
Summary Despite INMD being down -22% since I recommended to Buy the stock in March, InMode Ltd. remains a highly profitable & innovative leader in the aesthetic industry. Stronger than expected macroeconomic pressures and the slow but continuing escalation of the conflict in the Middle-East keep pushing the stock lower. Although I believe INMD remains significantly undervalued, the unpredictable situation in Israel as well as a probable FY2024 guidance miss are key risks that warrant caution. I am therefore downgrading INMD to Hold. I remain long for the mid-term upside potential, but I don’t expect upside catalysts before 2025. Read the full article on Seeking AlphaAnalyse-artikel • Aug 04
Here's What Analysts Are Forecasting For InMode Ltd. (NASDAQ:INMD) Following Its Earnings Miss
InMode Ltd. ( NASDAQ:INMD ) missed earnings with its latest second-quarter results, disappointing overly-optimistic...Seeking Alpha • Jun 13
InMode: Reversing Previous Shareholder Dilution With Buybacks
Summary Shareholders of InMode Ltd. have seen a 46% decline in value due to slowing sales and capital allocation uncertainties. Sales growth has been impacted by rising interest rates affecting leasing deals, leading to lower revenue growth projections for 2024. The company's new share repurchase program should reverse the dilution shareholders previously experienced. The low expectations embedded into the company's valuation makes it ripe for a revision higher. Read the full article on Seeking AlphaAnalyse-artikel • May 29
Lacklustre Performance Is Driving InMode Ltd.'s (NASDAQ:INMD) Low P/E
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") above 18x, you may...Seeking Alpha • May 08
InMode: Facing A Myraid Of Headwinds
Summary InMode's growth has plummeted due to sales execution issues, manufacturing delays, reduced demand, and high interest rates. INMD's business seems heavily reliant on economic conditions, beyond management's control. Shareholders expressed frustration with management's capital allocation decisions. I rate the company as a hold for now. Read the full article on Seeking AlphaRendement voor aandeelhouders
| INMD | US Medical Equipment | US Markt | |
|---|---|---|---|
| 7D | -0.07% | -5.5% | -0.9% |
| 1Y | 0.3% | -18.1% | 13.9% |
Rendement versus industrie: INMD overtrof de US Medical Equipment industrie, die het afgelopen jaar een rendement -18.1 % opleverde.
Rendement versus markt: INMD presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 13.9 % opleverde.
Prijsvolatiliteit
| INMD volatility | |
|---|---|
| INMD Average Weekly Movement | 3.8% |
| Medical Equipment Industry Average Movement | 8.2% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.9% |
Stabiele aandelenkoers: INMD heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 4% ) van INMD is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2008 | 660 | Moshe Mizrahy | www.inmodemd.com |
InMode Ltd. ontwerpt, ontwikkelt, produceert en verkoopt minimaal invasieve esthetische medische producten gebaseerd op haar eigen radiofrequentie ondersteunde lipolyse en diepe subdermale fractionele radiofrequentietechnologieën in de Verenigde Staten, Europa, Azië en internationaal. Het bedrijf biedt minimaal invasieve esthetische medische producten voor verschillende procedures, zoals liposuctie met gelijktijdige huidverstrakking, contouring van lichaam en gezicht en ablatieve huidverjongingsbehandelingen, evenals voor gebruik bij medische aandoeningen en procedures voor vrouwen. Het bedrijf ontwerpt, ontwikkelt, produceert en verkoopt ook niet-invasieve medisch-esthetische producten die gericht zijn op een reeks procedures, waaronder permanente haarreductie, huidverjonging in het gezicht, rimpelreductie, cellulitisbehandeling, huiduiterlijk en -textuur en oppervlakkige goedaardige vasculaire en gepigmenteerde laesies.
InMode Ltd. Samenvatting
| INMD fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$856.46m |
| Inkomsten(TTM) | US$77.51m |
| Inkomsten(TTM) | US$374.63m |
11.0x
Koers/Winstverhouding2.3x
P/S-verhoudingIs INMD overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| INMD resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$374.63m |
| Kosten van inkomsten | US$87.95m |
| Brutowinst | US$286.68m |
| Overige uitgaven | US$209.16m |
| Inkomsten | US$77.51m |
Laatst gerapporteerde inkomsten
Jun 30, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | 1.35 |
| Brutomarge | 76.52% |
| Nettowinstmarge | 20.69% |
| Schuld/Eigen Vermogen Verhouding | 0% |
Hoe presteerde INMD op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/09/14 16:24 |
| Aandelenkoers aan het einde van de dag | 2026/09/11 00:00 |
| Inkomsten | 2026/06/30 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
InMode Ltd. wordt gevolgd door 11 analisten. 6 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| null null | Baird |
| Jeffrey Johnson | Baird |
| Travis Steed | Barclays |